Discovered only a decade ago, the role of nitric oxide (NO) as a neurotransmitter is now a central feature of models describing a wide variety of brain functions. 1, 2 NO is synthesized from l-arginine. There are at least three distinct nitric oxide synthase (NOS) enzyme isoforms: a neuronal form (nNOS), an endothelial form (eNOS), and an inducible form (iNOS). In normal brain, nNOS is the principal isoform, and high concentrations of the nNOS protein are found in a small number of interneurons. These cells are responsible for much of the endogenous neural NO synthesis, and for the most part are the same neurons which are revealed by the classic histochemical NADPH diaphorase staining technique. 3 In contrast to classical neurotransmitters, NO is neither stored nor released; once synthesized, it travels by passive diffusion across membranes. Consequently, the principal means of regulating brain NO is through control of NOS activity. The most potent activator of NOS is the N-methyl-d-aspartate (NMDA) type of glutamate receptor. 1, 4 Recent work in our laboratory and by others has revealed two new and important aspects of the interaction of NMDA receptors with NOS. First, the structure and properties of the NMDA receptors present in neurons with high concentrations of nNOS appear to differ substantially from the NMDA receptors found in most other neurons in the brain. Second, the interaction of NMDA receptor proteins with nNOS appears to be facilitated by a 'molecular scaffold' of proteins present at the postsynaptic density, which maintain all the required components of the signaling mechanism in close physical proximity.
These developments are best understood in the context of the rapidly increasing understanding of the structure and regulation of glutamate receptors in the brain. Using classic pharmacologic techniques, four distinct types of glutamate receptor were defined: three 'ionotropic' or channel-forming types, with preference for NMDA, AMPA or kainate; and a 'metabotropic' or G-protein coupled type. 5 The first protein subunit of 6 Since that time, at least 13 additional ionotropic subunits, many with multiple isoforms, have been uncovered. There are also eight distinct metabotropic receptors, and several 'orphan' subunits with strong sequence homology but ill-defined function. 7 A great deal of effort is presently focussed on understanding the rules governing assembly of the ionotropic receptor subunits into receptors, the regulation and targeting of the assemblies within neurons, and the properties of the different receptors that may be formed.
NMDA receptor subunits are from two distinct families. 8 The NMDAR1 family is encoded by a single gene with 22 exons. Three of these exons may be variably spliced, giving rise to eight distinct isoforms. 9 The NMDAR2 consists of four separate genes each encoding a single protein. 10, 11 The true subunit composition of native NMDA receptors is unknown, but it is thought that at least one member from each family must be present to form a functional channel. The isoforms of NMDAR1 and NMDAR2 present in the receptor complex determine many of the physiologic properties of the channel.
In a recent study, we examined the NMDAR1 proteins present in rat forebrain neurons containing high levels of nNOS, using a panel of antisera to segments of NMDAR1 and dual-label confocal microscopy. 12 We found that the NMDAR1 proteins present in nNOS neurons in the cortex, hippocampus and striatum differed substantially from those of most other neurons in these brain structures. In particular, nNOS neurons contained isoforms lacking both of the carboxy variably spliced segments of NMDAR1. The first of these, termed 'C1' is 37 amino acids long. It is thought to be an important regulatory region because it contains a high affinity binding site for calmodulin, which inhibits channel activity, as well as sites for phosphorylation by protein kinases A and C. 13, 14 The second variably spliced region determines the carboxy terminus of the NMDAR1. Two distinct sequences, C2 and C2Ј, are possible depending on which of two alternative splice acceptor sites within exon 22 are employed. Forebrain nNOS neurons contain large amounts of the C2Ј form.
The abundance of subunits bearing the C2Ј terminus is of particular interest because of recent work defining the interaction of NMDA receptor subunits with other proteins found at post-synaptic sites. 15 It is becoming increasingly clear that there is a highly specialized apparatus present which is responsible for clustering receptors at appropriate locations, and ensuring close proximity of components of the effector mechanisms. The first protein of this class to be described is PSD-95. 16, 17 This protein contains three 'PDZ' domains, segments responsible for protein-protein interaction. 18 The C2Ј segment of NMDAR1 (but not the C2 segment) contains a consensus site for interaction with the PDZ domains of PSD-95, as do the NMDAR2 subunits. Interestingly, nNOS also binds strongly to PSD-95 through a PDZ interaction. 19 Thus, PSD-95 may serve to anchor NMDA receptors, especially those containing NMDAR1-C2Ј segments, in close proximity to nNOS.
An unusual NMDAR1 isoform is not the only distinguishing feature of the receptors found in nNOS neurons. They also express the mRNA for the NMDAR2D, a subunit which is abundant early in neural development but in adult rat brain is restricted to a relatively small number of neurons. 20, 21 Among these are several types of interneurons, including those with a high level of nNOS as well as other cholinergic and GABAergic types. In vitro, channels containing NMDAR2D subunits have unusual properties, including very long channel open times and insensitivity to blockade by magnesium ion. 22 It has been pointed out that these might be desirable properties of interneurons in that they would allow the integration of input signals over time. 10 They may also be relevant to the activation of nNOS by NMDA receptors, producing prolonged activation after brief stimulation.
These recent insights into the NMDA receptors regulating NO synthesis are part of a larger evolution of insight into the specificity and coupling of NMDA receptors in the brain as a whole. It is increasingly clear that particular types of neurons express receptors with distinct subunit composition and functional properties. Furthermore, NMDA receptors cannot be viewed as simple ion channels, but rather they are surface proteins linked to a complex, tightly coupled intracellular effector machinery. From a therapeutic point of view, these developments are exciting because they suggest the possibility of producing drugs which would inhibit the NMDA receptors present on nNOS neurons without unduly affecting vital NMDA-mediated communication in other parts of the brain.
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